Halozyme Therapeutics, Inc. (HALO)
95.75
-0.22
(-0.23%)
USD |
NASDAQ |
Nov 18, 16:00
96.00
+0.25
(+0.26%)
After-Hours: 20:00
Halozyme Therapeutics Price : 95.75 for Nov. 18, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 95.99 | 97.01 | 94.93 | 95.97 | 2.041M |
| Nov 16, 2026 | 101.72 | 101.75 | 96.40 | 96.50 | 2.088M |
| Nov 13, 2026 | 100.32 | 101.22 | 99.26 | 100.27 | 2.276M |
| Nov 12, 2026 | 101.58 | 102.14 | 100.27 | 100.67 | 1.431M |
| Nov 11, 2026 | 101.26 | 102.62 | 99.27 | 101.68 | 2.505M |
| Nov 10, 2026 | 101.92 | 105.45 | 101.38 | 102.98 | 2.252M |
| Nov 09, 2026 | 103.98 | 105.64 | 101.04 | 102.92 | 2.927M |
| Nov 06, 2026 | 117.03 | 118.26 | 102.52 | 103.63 | 6.163M |
| Nov 05, 2026 | 130.64 | 131.44 | 122.77 | 122.96 | 2.897M |
| Nov 04, 2026 | 130.81 | 130.98 | 126.86 | 130.34 | 1.613M |
| Nov 03, 2026 | 128.29 | 131.36 | 128.26 | 128.62 | 1.496M |
| Nov 02, 2026 | 130.50 | 131.89 | 127.52 | 128.95 | 3.364M |
| Oct 30, 2026 | 132.66 | 134.00 | 130.30 | 130.91 | 1.402M |
| Oct 29, 2026 | 131.06 | 132.55 | 130.09 | 131.18 | 1.875M |
| Oct 28, 2026 | 126.78 | 130.24 | 126.25 | 130.03 | 1.725M |
| Oct 27, 2026 | 127.21 | 128.94 | 126.13 | 128.50 | 1.700M |
| Oct 26, 2026 | 126.03 | 128.11 | 126.03 | 128.01 | 1.238M |
| Oct 23, 2026 | 124.54 | 126.23 | 123.74 | 125.63 | 1.530M |
| Oct 22, 2026 | 124.72 | 124.91 | 121.62 | 124.54 | 5.098M |
| Oct 21, 2026 | 123.90 | 125.43 | 122.71 | 124.83 | 1.716M |
| Oct 20, 2026 | 123.54 | 125.10 | 123.00 | 124.37 | 2.149M |
| Oct 19, 2026 | 121.72 | 123.60 | 121.68 | 122.50 | 1.894M |
| Oct 16, 2026 | 122.19 | 122.44 | 120.19 | 121.84 | 2.083M |
| Oct 15, 2026 | 118.35 | 122.33 | 117.38 | 121.51 | 2.470M |
| Oct 14, 2026 | 109.90 | 119.21 | 109.42 | 116.82 | 3.770M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Iovance Biotherapeutics, Inc. | 7.485 |
| AVITA Medical, Inc. | 16.80 |
| Merck & Co., Inc. | 138.48 |
| TG Therapeutics, Inc. | 66.12 |
| Agenus, Inc. | 6.39 |
Price Related Metrics
| PE Ratio | 24.37 |
| PS Ratio | 6.433 |
| Price to Free Cash Flow | 13.09 |
| Earnings Yield | 4.10% |
| Market Cap | 10.91B |
| Operating PE Ratio | 11.35 |
| Normalized PE Ratio | 15.88 |